| Previous Close | 82.30 |
| Open | 82.47 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 82.43 - 84.25 |
| 52 Week Range | 24.55 - 92.97 |
| Volume | 804,056 |
| Avg. Volume | 1,816,660 |
| Market Cap | 102.47B |
| Beta | 0.73 |
| PE Ratio (TTM) | 11.74 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.40%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- MarketWatch•yesterday
UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment
Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares ...
- Motley Fool•yesterday
Why Exelixis Wouldn't Be a Warren Buffett Stock
Buffett and biotech mix like oil and water.
- Market Realist•3 days ago
Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017
Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.
